Navigation Links
BioLineRx to Present at Biotech Showcase Conference in San Francisco
Date:1/7/2014

JERUSALEM, Jan. 7, 2014 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the Biotech Showcase 2014 Conference being held at the Parc 55 Wyndham Union Square Hotel in San Francisco, CA.

(Logo: http://photos.prnewswire.com/prnh/20130730/630769 )

The BioLineRx presentation is scheduled to start at 11:30 a.m. PST (2:30 p.m. EST) on Tuesday, January 14, 2014. A live audio webcast of the presentation will be available online at BioLineRx's investor web page. An archive of the event will also be available for those unable to listen live.

About BioLineRx

BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc. and is in the midst of a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions, which is expected to commence a pivotal CE-mark registration trial in early 2014; BL-8040 for treating acute myeloid leukemia (AML) and other hematological indications, which is in the midst of a Phase 2 study; and BL-7010 for celiac disease, which recently commenced a Phase 1/2 study.

For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store.

Contact: 
Tiberend Strategic Advisors, Inc. 
Joshua Drumm, Ph.D. 
jdrumm@tiberend.com 
(212) 375-2664 
Andrew Mielach 
amielach@tiberend.com 
(212) 375-2694 

Or 

Tsipi Haitovsky 
Public Relations
+972-3-6240871
tsipih@netvision.net.il


'/>"/>
SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia
2. BioLineRx Reports Second Quarter 2013 Results
3. BioLineRx Appoints B. J. Bormann to Board of Directors
4. BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston
5. BioLineRx to Present at 15th International Celiac Disease Symposium
6. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
7. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
8. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
9. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
10. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
11. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 2016 BioNovus Innovations LLC and the ... Medical Innovation (IAMI) today announced a new partnership ... medical devices. An agreement between the ... license, develop and commercialize medical innovations advanced through ... partnership represents a significant advance in our ability ...
(Date:5/3/2016)... May 3, 2016  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further expand product development, ... - http://photos.prnewswire.com/prnh/20160503/362921 ... ... ... ...
(Date:5/3/2016)... BROOMALL, Pa. , May 3, 2016 ... Attorney Jack Whelan and Delaware County ... NARCAN® (naloxone HCI) Nasal Spray in all ACME ... the U.S. Centers for Disease Control and Prevention (CDC), naloxone has ... 2014, when police officers in Delaware County ...
Breaking Medicine Technology:
(Date:5/6/2016)... TX (PRWEB) , ... May 06, 2016 , ... ... of Bluvault's Integration Service, their latest implementation service offering for global clients of ... ( Appterra ). , Bluvault’s Integration Service is a key component in ...
(Date:5/6/2016)... IL (PRWEB) , ... May 06, 2016 , ... From ... in Chicago, IL, offering EarQ members the unique opportunity to learn more about Signia’s ... for independent practice growth. , “It is our priority to see practices succeed in ...
(Date:5/6/2016)... San Diego, CA (PRWEB) , ... May 06, 2016 , ... ... of Companies, has been family-owned and operated for over 35 years. Maintaining core values ... community has driven their success and made them a leading name in San Diego ...
(Date:5/6/2016)... ... May 06, 2016 , ... Kenneth Cochran, DSc, ... Cardiovascular Institute of the South announced today that Dr. Robert Menuet, Interventional Cardiologist ... an Intravascular Ultrasound Guided Coronary Atherectomy. , This procedure involves the ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... in the industry’s gold standard KLAS Performance Report, Epic Consulting 2016 ... assessed organizations that specialize in consulting services for electronic health record (EHR) solutions ...
Breaking Medicine News(10 mins):